Asklepios BioPharmaceutical

Brainvectis is focused on the development of treatments that focus on neurodegenerative diseases such as Huntington’s and Alzheimer’s diseases. It researches about the restoration of brain cholesterol metabolism by increasing CYP46A1 in the patients’ brains. Brainvectis was founded by Nathalie Cartier Lacave in 2015. It is based in Fontenay-aux-Roses, France.

RoverMed develops precision targeted drug delivery technology aimed at delivering life saving drugs to the most challenging diseases in hard to reach places in the body. RoverMed has developed targeted, twenty nanometer nanocapsule technology capable of reaching the most challenging disease sites and delivering cargo – intact – into the nucleus of target cells, regardless of where these cells are located in the body. RoverMed’s nanocapsule technology has been proven, through years of intensive research and development, by Minnesota-based GeneSegues Therapeutics. A precision target drug delivery platform has been developed initially for solid tumor cancers of the head and neck, prostate, and colon. RoverMed is now applying this technology toward a broader spectrum of treatment applications, in partnership with larger drug developers, in order to expand the acceptance, use and impact on a host of new, exciting applications. Our business model includes partnering our drug delivery technology with our partner's drugs to advance novel therapeutics aimed at treating some of the most challenging diseases that are not well served by traditional therapeutic options.

Synpromics develops and commercializes synthetic promoters to control gene expressions and regulations. The company was founded in 2010 and is based in Edinburgh, United Kingdom.